Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer

Pfizer's payout ratio looks far too high. However, the company's dividend has increased despite headwinds in recent years.

The Motley Fool • 16 hours ago

PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use

Pfizer's Talzenna plus Xtandi combo wins FDA priority review for HRR gene-mutated metastatic castration-sensitive prostate cancer.

Zacks Investment Research • 20 hours ago

Pfizer's prostate cancer drug combination gets US FDA priority review

Pfizer said on Wednesday the U.S. ​Food and Drug Administration has ‌granted priority review to its application seeking expanded approval for its prostate ​cancer treatment combination.

Reuters • Jul 22, 2026

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC), also known as meta.

Business Wire • Jul 22, 2026

2 Absurdly Cheap Healthcare Stocks to Buy Before July Ends

Healthcare is quietly becoming the value hunter's playground of 2026. While the mega cap tech trade keeps sucking up oxygen, two of the largest healthcare names in the S&P 500 are trading at forward multiples that look mispriced against their earnings power.

24/7 Wall Street • Jul 22, 2026

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

President Donald ​Trump said ‌on Tuesday all generic drugs ​being ​brought into the ⁠U.S. will ​continue having ​a tariff of 0% for two ​years ​starting from August 1, ‌after ⁠which the tariff rate will be ​raised ​to ⁠100% for ​one year ​and ⁠to 200% thereafter.

Reuters • Jul 21, 2026

What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season

Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.

Zacks Investment Research • Jul 21, 2026

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Pfizer has an attractive weight loss pipeline. However, it will be hard to take the lead from other companies in this fast-growing area.

The Motley Fool • Jul 20, 2026

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Jul 20, 2026

Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know

In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous day.

Zacks Investment Research • Jul 20, 2026